聖濟堂(600227.SH):子公司聖濟堂製藥保健品生產線搬遷進展暨獲得保健品生產許可證
格隆匯9月14日丨聖濟堂(600227.SH)公佈,公司保健食品原主要產品有聖濟堂牌衡之源膠囊、聖濟堂牌壹力源膠囊、聖濟堂牌壹源清膠囊。公司進行再註冊時根據《保健食品命名指南(2019年版)》的要求對上述三個產品重新命名為聖濟堂牌椹杞膠囊、聖濟堂牌黃芪參杞膠囊、聖濟堂牌苦瓜桑鉻膠囊,產品配方等均與原產品一致。為了儘快恢復公司保健品的生產,公司決定對可進行外購原料的聖濟堂牌苦瓜桑鉻膠囊生產線進行生產許可認證申請。
2021年9月14日,聖濟堂製藥收到貴州省市場監督管理局頒發的食品生產許可證,類別為保健食品。
此次保健食品生產許可認證生產線為保健食品硬膠囊劑車間,通過認證的品種為聖濟堂牌苦瓜桑鉻膠囊,公司保健食品硬膠囊車間的正式生產將對公司糖尿病藥品的銷售起到一定協同作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.